阿爾法企業(00948.HK)擬配售最多3492萬股籌資4780萬港元
格隆匯3月31日丨阿爾法企業(00948.HK)公佈,於2022年3月31日,公司與配售代理訂立配售協議,公司擬按配售價每股配售股份1.40港元(較3月31日收市價每股股份1.370港元溢價2.19%)配售最多3492萬股,相當於現有已發行股本約11.11%及經配發及發行所有配售股份擴大後已發行股本約10.00%。
配售事項的所得款項總額將為4890萬港元及所得款項淨額(經扣除配售事項的佣金及其他開支後)約為4780萬港元,董事擬將所得款項淨額用作(i)於奶類產品業務的發展及/或投資;及(ii)集團一般營運資金。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.